Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics

Sun Ju Byeon, Hwa Jin Cho, Hae Woon Baek, Chul Kee Park, Seung Hong Choi, SeHoon Kim, Hee Kyung Kim, Sung Hye Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The clinicopathologic and molecular genetic features of 5 cases of rhabdoid glioblastoma, an extremely rare variant of glioblastoma that tends to affect patients at a young age, were investigated by immunohistochemical analysis and focused molecular genetic studies including array-based comparative genomic hybridization. All 5 cases had supratentorial tumors that immunohistochemical analysis revealed to be robustly positive for epithelial membrane antigen, vimentin, p53, and PDGFRα (platelet-derived growth factor receptor, alpha polypeptide) but only focally positive for glial fibrillary acidic protein. Although complete retention of SMARCB1 (INI1) was observed in all 5 cases, epidermal growth factor receptor (EGFR) amplification, PTEN (phosphatase and tensin homolog) loss, homozygous deletion of cyclin-dependent kinase inhibitor 2A, 1p/19q codeletion, and isocitrate dehydrogenase 1 R132/IDH2 R172 mutation were not observed in any case, although a high level of EGFR polysomy was detected in 1 recurrent tumor. Although c-MET (MET protein) expression was focal but robustly positive in 3 cases, met proto-oncogene (MET) fluorescence in situ hybridization revealed low polysomy but not MET amplification. MGMT (O-6-methylguanine-DNA methyl-40 transferase) methylation-specific polymerase chain reaction revealed MGMT methylation in only 1 case. Furthermore, array-based comparative genomic hybridization revealed gain of chromosome 7 and loss of 1p, 6, 8p, 11, 13q, and 18q but no deletion of chromosome 22. In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide.

Original languageEnglish
Pages (from-to)611-620
Number of pages10
JournalHuman Pathology
Volume45
Issue number3
DOIs
Publication statusPublished - 2014 Mar 1

Fingerprint

Glioblastoma
Cytogenetics
Molecular Biology
Epidermal Growth Factor Receptor
Platelet-Derived Growth Factor alpha Receptor
Comparative Genomic Hybridization
temozolomide
Transferases
Phosphoric Monoester Hydrolases
Methylation
Supratentorial Neoplasms
Cyclin-Dependent Kinase Inhibitor p16
Isocitrate Dehydrogenase
Chromosomes, Human, Pair 22
Mucin-1
Peptides
Chromosomes, Human, Pair 7
Proto-Oncogenes
Glial Fibrillary Acidic Protein
DNA

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Byeon, Sun Ju ; Cho, Hwa Jin ; Baek, Hae Woon ; Park, Chul Kee ; Choi, Seung Hong ; Kim, SeHoon ; Kim, Hee Kyung ; Park, Sung Hye. / Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. In: Human Pathology. 2014 ; Vol. 45, No. 3. pp. 611-620.
@article{5a0a110bbaa94e31bf86f29a7aedaf05,
title = "Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics",
abstract = "The clinicopathologic and molecular genetic features of 5 cases of rhabdoid glioblastoma, an extremely rare variant of glioblastoma that tends to affect patients at a young age, were investigated by immunohistochemical analysis and focused molecular genetic studies including array-based comparative genomic hybridization. All 5 cases had supratentorial tumors that immunohistochemical analysis revealed to be robustly positive for epithelial membrane antigen, vimentin, p53, and PDGFRα (platelet-derived growth factor receptor, alpha polypeptide) but only focally positive for glial fibrillary acidic protein. Although complete retention of SMARCB1 (INI1) was observed in all 5 cases, epidermal growth factor receptor (EGFR) amplification, PTEN (phosphatase and tensin homolog) loss, homozygous deletion of cyclin-dependent kinase inhibitor 2A, 1p/19q codeletion, and isocitrate dehydrogenase 1 R132/IDH2 R172 mutation were not observed in any case, although a high level of EGFR polysomy was detected in 1 recurrent tumor. Although c-MET (MET protein) expression was focal but robustly positive in 3 cases, met proto-oncogene (MET) fluorescence in situ hybridization revealed low polysomy but not MET amplification. MGMT (O-6-methylguanine-DNA methyl-40 transferase) methylation-specific polymerase chain reaction revealed MGMT methylation in only 1 case. Furthermore, array-based comparative genomic hybridization revealed gain of chromosome 7 and loss of 1p, 6, 8p, 11, 13q, and 18q but no deletion of chromosome 22. In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide.",
author = "Byeon, {Sun Ju} and Cho, {Hwa Jin} and Baek, {Hae Woon} and Park, {Chul Kee} and Choi, {Seung Hong} and SeHoon Kim and Kim, {Hee Kyung} and Park, {Sung Hye}",
year = "2014",
month = "3",
day = "1",
doi = "10.1016/j.humpath.2013.08.024",
language = "English",
volume = "45",
pages = "611--620",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "3",

}

Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. / Byeon, Sun Ju; Cho, Hwa Jin; Baek, Hae Woon; Park, Chul Kee; Choi, Seung Hong; Kim, SeHoon; Kim, Hee Kyung; Park, Sung Hye.

In: Human Pathology, Vol. 45, No. 3, 01.03.2014, p. 611-620.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics

AU - Byeon, Sun Ju

AU - Cho, Hwa Jin

AU - Baek, Hae Woon

AU - Park, Chul Kee

AU - Choi, Seung Hong

AU - Kim, SeHoon

AU - Kim, Hee Kyung

AU - Park, Sung Hye

PY - 2014/3/1

Y1 - 2014/3/1

N2 - The clinicopathologic and molecular genetic features of 5 cases of rhabdoid glioblastoma, an extremely rare variant of glioblastoma that tends to affect patients at a young age, were investigated by immunohistochemical analysis and focused molecular genetic studies including array-based comparative genomic hybridization. All 5 cases had supratentorial tumors that immunohistochemical analysis revealed to be robustly positive for epithelial membrane antigen, vimentin, p53, and PDGFRα (platelet-derived growth factor receptor, alpha polypeptide) but only focally positive for glial fibrillary acidic protein. Although complete retention of SMARCB1 (INI1) was observed in all 5 cases, epidermal growth factor receptor (EGFR) amplification, PTEN (phosphatase and tensin homolog) loss, homozygous deletion of cyclin-dependent kinase inhibitor 2A, 1p/19q codeletion, and isocitrate dehydrogenase 1 R132/IDH2 R172 mutation were not observed in any case, although a high level of EGFR polysomy was detected in 1 recurrent tumor. Although c-MET (MET protein) expression was focal but robustly positive in 3 cases, met proto-oncogene (MET) fluorescence in situ hybridization revealed low polysomy but not MET amplification. MGMT (O-6-methylguanine-DNA methyl-40 transferase) methylation-specific polymerase chain reaction revealed MGMT methylation in only 1 case. Furthermore, array-based comparative genomic hybridization revealed gain of chromosome 7 and loss of 1p, 6, 8p, 11, 13q, and 18q but no deletion of chromosome 22. In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide.

AB - The clinicopathologic and molecular genetic features of 5 cases of rhabdoid glioblastoma, an extremely rare variant of glioblastoma that tends to affect patients at a young age, were investigated by immunohistochemical analysis and focused molecular genetic studies including array-based comparative genomic hybridization. All 5 cases had supratentorial tumors that immunohistochemical analysis revealed to be robustly positive for epithelial membrane antigen, vimentin, p53, and PDGFRα (platelet-derived growth factor receptor, alpha polypeptide) but only focally positive for glial fibrillary acidic protein. Although complete retention of SMARCB1 (INI1) was observed in all 5 cases, epidermal growth factor receptor (EGFR) amplification, PTEN (phosphatase and tensin homolog) loss, homozygous deletion of cyclin-dependent kinase inhibitor 2A, 1p/19q codeletion, and isocitrate dehydrogenase 1 R132/IDH2 R172 mutation were not observed in any case, although a high level of EGFR polysomy was detected in 1 recurrent tumor. Although c-MET (MET protein) expression was focal but robustly positive in 3 cases, met proto-oncogene (MET) fluorescence in situ hybridization revealed low polysomy but not MET amplification. MGMT (O-6-methylguanine-DNA methyl-40 transferase) methylation-specific polymerase chain reaction revealed MGMT methylation in only 1 case. Furthermore, array-based comparative genomic hybridization revealed gain of chromosome 7 and loss of 1p, 6, 8p, 11, 13q, and 18q but no deletion of chromosome 22. In contrast to the classical subtype of primary glioblastoma, the cases studied here were characterized by the absence of EGFR amplification, PTEN loss, and 9p homozygous deletion and overexpression of p53, PDGFRα, and c-MET, suggesting that they can be classified as the proneural or mesenchymal subtype of glioblastoma and benefit from intensive therapy that includes temozolomide.

UR - http://www.scopus.com/inward/record.url?scp=84894095598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894095598&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2013.08.024

DO - 10.1016/j.humpath.2013.08.024

M3 - Article

C2 - 24457079

AN - SCOPUS:84894095598

VL - 45

SP - 611

EP - 620

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 3

ER -